惠普森医药 2026年季度报告

FORM 10-Q (Mark One)☒QUARTERLY REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period endedJune 30, 2026 ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from ____________ to ____________ Commission File Number 001-34471 CHINA PHARMA HOLDINGS, INC.(Exact name of registrant as specified in its charter) +86-898-6681-1730(China)(Registrant’s telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Name of each exchange on whichregistered NYSE American Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of theSecurities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to filesuch reports), and (2) has been subject to such filing requirements for the past 90 days. Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to besubmitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorterperiod that the registrant was required to submit and post such files). Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smallerreporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filer☐Non-accelerated filer☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition periodfor complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes☐No☒ As of August 11, 2026, there were 43,022,002 shares of common stock, $0.001 par value per share, issued and outstanding. CHINA PHARMA HOLDINGS, INC. AND SUBSIDIARIES TABLE OF CONTENTS PART I FINANCIAL INFORMATION1Item 1.Financial Statements1Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations18Item 3.Quantitative and Qualitative Disclosures about Market Risk26Item 4.Controls and Procedures26PART II OTHER INFORMATION27Item 6.Exhibits27 PART I – FINANCIAL INFORMATION CHINA PHARMA HOLDINGS, INC. AND SUBSIDIARIES TABLE OF CONTENTS Condensed Consolidated Balance Sheets as of June 30, 2026 and December 31, 2025 (Unaudited)2Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three Months and Six MonthsEnded June 30, 2026 and 2025 (Unaudited)3Condensed Consolidated Statements of Stockholders’ Equity for the Six Months Ended June 30, 2026 and 2025(Unaudited)4Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2026 and 2025 (Unaudited)5Notes to Condensed Consolidated Financial Statements (Unaudited)6 CHINA PHARMA HOLDINGS, INC.CONDENSED CONSOLIDATED BALANCE SHEETSAMOUNTS IN U.S. DOLLARS, EXCEPT FOR SHARE DATA(Unaudited) Cash and cash equivalents$304,874$345,112Bankers acceptances1,825-Trade accounts receivable, less allowance for credit losses of $14,228 and $13,023181,621241,412Other receivables, less allowance for credit losses of $35,083 and $32,153, respectively66,62749,261Advances to suppliers2,2836,831Inventories1,362,4231,621,423Prepaid expenses86,96582,368Total Current Assets2,006,6182,346,407Property, plant and equipment, net4,219,7634,391,964Right-of-use assets146,181181,828Intangible assets, net38,337,34124,079,265TOTAL ASSETS$ 44,709,903$ 30,999,464 CHINA PHARMA HOLDINGS, INC.CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONSAND COMPREHENSIVE LOSSAMOUNTS IN U.S. DOLLARS, EXCEPT FOR SHARE DATA(Unaudited) CHINA PHARMA HOLDINGS, INC.CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITYAMOUNTS IN U.S. DOLLARS, EXCEPT FOR SHARE DATA(Unaudited) CHINA PHARMA HOLDINGS, INC.NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTSSIX MONTHS ENDED JUNE 30, 2026 AND 2025 (UNAUDITED) NOTE 1 – ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES Organization and Nature of Operations –China Pharma Holdings, Inc., a Nevada corporation (“China Pharma”), owns 100% ofOnny Investment Limited (“Onny”), a British Virgin Islands corporation, which owns 100% of Hainan Helpson Medical &Biotechnology Co., Ltd (“Helpson”), a company organized under the laws of the People’s Republic of China (the “PRC”). ChinaPharma Holdings, Inc. and its subsidiaries are referred to herein as the Company. Onny acquired 100% of the ownership of Helpson on May 25, 2005, by entering into an Equity Transfer Agreement with Helpson’sthree former shareholders. The transaction was approved by the Commercial Bureau of Hainan Pro